Tetrathiomolybdate
- Generic Name
- Tetrathiomolybdate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- MoS4
- CAS Number
- 16330-92-0
- Unique Ingredient Identifier
- 91U3TGV99T
- Background
Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is dependent upon the av...
- Indication
Investigated for use/treatment in liver disease and pulmonary fibrosis.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
- Conditions
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 204
- Registration Number
- NCT06134375
- Locations
- 🇺🇸
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2019-07-19
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 26
- Registration Number
- NCT01837329
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- George Brewer
- Target Recruit Count
- 29
- Registration Number
- NCT00805805
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00195091
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 23
- Registration Number
- NCT00189176
- Locations
- 🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States
Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-02-07
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00176774
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Tetrathiomolybdate in Hormone Refractory Prostate Cancer
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-01-21
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT00150995
- Locations
- 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Treatment of Hepatocellular Carcinoma With Tetrathiomolybdate
- Conditions
- First Posted Date
- 2000-10-05
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00006332
- Locations
- 🇺🇸
3912 Taubman Center, Ann Arbor, Michigan, United States
Study of Tetrathiomolybdate in Patients With Wilson Disease
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2006-05-09
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 90
- Registration Number
- NCT00004339
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.